NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
申请人:Ogeda SA
公开号:US10065960B2
公开(公告)日:2018-09-04
The present invention is directed to novel compounds of formula I
and their use as therapeutic compounds.
本发明涉及式 I 的新型化合物
及其作为治疗化合物的用途。